-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
RedHill Biopharma (NASDAQ:RDHL) Stock Passes Below 200 Day Moving Average of $1.38
RedHill Biopharma (NASDAQ:RDHL) Stock Passes Below 200 Day Moving Average of $1.38
RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Rating)'s share price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.38 and traded as low as $0.85. RedHill Biopharma shares last traded at $0.89, with a volume of 393,337 shares.
RedHill Biopharma Price Performance
The company has a debt-to-equity ratio of 9.42, a current ratio of 0.98 and a quick ratio of 0.79. The stock has a market capitalization of $46.82 million, a P/E ratio of -0.47 and a beta of 1.80. The company's 50 day simple moving average is $0.94 and its two-hundred day simple moving average is $1.38.
Get RedHill Biopharma alerts:RedHill Biopharma (NASDAQ:RDHL – Get Rating) last released its quarterly earnings results on Thursday, June 23rd. The biotechnology company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.10. RedHill Biopharma had a negative net margin of 110.31% and a negative return on equity of 822.29%. The business had revenue of $18.24 million for the quarter. During the same period last year, the company earned ($0.53) earnings per share. As a group, equities analysts expect that RedHill Biopharma Ltd. will post -0.83 EPS for the current fiscal year.
Institutional Investors Weigh In On RedHill Biopharma
A number of hedge funds and other institutional investors have recently made changes to their positions in RDHL. Disciplined Growth Investors Inc. MN increased its stake in RedHill Biopharma by 0.7% in the 1st quarter. Disciplined Growth Investors Inc. MN now owns 1,950,002 shares of the biotechnology company's stock valued at $4,914,000 after buying an additional 14,413 shares during the last quarter. ARK Investment Management LLC grew its position in shares of RedHill Biopharma by 21.3% in the 2nd quarter. ARK Investment Management LLC now owns 1,045,023 shares of the biotechnology company's stock valued at $1,170,000 after acquiring an additional 183,225 shares during the period. Millennium Management LLC bought a new position in shares of RedHill Biopharma in the 2nd quarter valued at about $324,000. Gagnon Securities LLC boosted its holdings in shares of RedHill Biopharma by 15.4% during the 1st quarter. Gagnon Securities LLC now owns 367,346 shares of the biotechnology company's stock worth $926,000 after buying an additional 49,023 shares during the period. Finally, BlackRock Inc. boosted its holdings in shares of RedHill Biopharma by 18.6% during the 1st quarter. BlackRock Inc. now owns 357,493 shares of the biotechnology company's stock worth $901,000 after buying an additional 56,178 shares during the period. 7.74% of the stock is currently owned by institutional investors and hedge funds.RedHill Biopharma Company Profile
(Get Rating)
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
Further Reading
- Get a free copy of the StockNews.com research report on RedHill Biopharma (RDHL)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Rating)'s share price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.38 and traded as low as $0.85. RedHill Biopharma shares last traded at $0.89, with a volume of 393,337 shares.
紅山生物醫藥股份有限公司(納斯達克代碼：RDHL-GET評級)的股價在週五的交易中跌破200日移動均線，200日移動均線為1.38美元，最低交易價格為0.85美元。紅山生物醫藥的股票最新報0.89美元，成交量為393,337股。
RedHill Biopharma Price Performance
紅山生物醫藥的價格表現
The company has a debt-to-equity ratio of 9.42, a current ratio of 0.98 and a quick ratio of 0.79. The stock has a market capitalization of $46.82 million, a P/E ratio of -0.47 and a beta of 1.80. The company's 50 day simple moving average is $0.94 and its two-hundred day simple moving average is $1.38.
該公司的債務權益比為9.42，流動比率為0.98，速動比率為0.79。該股市值為4,682萬美元，市盈率為-0.47，貝塔係數為1.80。該公司的50日簡單移動均線切入位為0.94美元，200日簡單移動均線切入位為1.38美元。
RedHill Biopharma (NASDAQ:RDHL – Get Rating) last released its quarterly earnings results on Thursday, June 23rd. The biotechnology company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.10. RedHill Biopharma had a negative net margin of 110.31% and a negative return on equity of 822.29%. The business had revenue of $18.24 million for the quarter. During the same period last year, the company earned ($0.53) earnings per share. As a group, equities analysts expect that RedHill Biopharma Ltd. will post -0.83 EPS for the current fiscal year.
紅山生物科技(納斯達克代碼：RDHL-GET Rating)最近一次發佈季度收益報告是在6月23日(星期四)。這家生物技術公司公佈了本季度每股收益(0.30美元)，比普遍預期的(0.40美元)高出0.10美元。紅山生物醫藥的淨利潤率為負110.31%，淨資產回報率為負822.29%。該業務本季度的收入為1824萬美元。去年同期，該公司每股收益為0.53美元。股票分析師預計，作為一個整體，紅山生物科技有限公司本財年每股收益將達到0.83歐元。
Institutional Investors Weigh In On RedHill Biopharma
機構投資者買入紅山生物醫藥
RedHill Biopharma Company Profile
紅山生物醫藥公司簡介
(Get Rating)
(獲取評級)
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
紅山生物製藥有限公司是一家專業的生物製藥公司，主要專注於胃腸道和傳染病。該公司推廣胃腸藥物，包括用於治療患有慢性非癌症疼痛的成人阿片類藥物引起的便祕的Movantik；用於治療成人幽門螺桿菌感染的Talicia；以及用於治療成人旅行者腹瀉的Aemcolo。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on RedHill Biopharma (RDHL)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免費獲取StockNews.com關於RedHill Biophma(RDHL)的研究報告
- MarketBeat：回顧一週9/5-9/9
- 為網絡安全股創紀錄的季度做準備
- 汽車市場正在緩慢復甦，這些股票可能表現優異
- DocuSign是否即將發生重大逆轉？
- 石油和天然氣股票：投資可再生能源的安全途徑
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受《紅山生物報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對RedHill Biophma和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧